Evie

Evie, on behalf of Gavin from Evercore ISI, requested an update on enrollment trends for the Panorama GAD trial and the Ascend MDD trial, given the Voyage data timeline. She also asked about additional factors, beyond the sample size re-estimation and variability, that are contributing to Definium's confidence in the ongoing trials.

Answer

Robert Barrow, CEO, reported rapid enrollment for Emerge, strong progress with Voyage at 80% completion, and anticipated updates for Panorama at the April Analyst Day. He noted Ascend's swift activation due to efficient DEA approvals. Mr. Barrow emphasized overall confidence in DT120's profile, citing Voyage's implied >99% power and a significantly lower non-evaluable rate (10%) compared to Phase II, attributed to the Part B open-label treatment option.